<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39355951</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1598-6357</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>37</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of Korean medical science</Title><ISOAbbreviation>J Korean Med Sci</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea.</ArticleTitle><Pagination><StartPage>e258</StartPage><MedlinePgn>e258</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e258</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3346/jkms.2024.39.e258</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This retrospective observational matched cohort study assessed the differences in critical infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the omicron-predominant period of the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the vaccine effectiveness of bivalent mRNA vaccine compared to unvaccinated individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We collected COVID-19 case data from the Korean COVID-19 vaccine effectiveness cohort. We calculated the probability of critical COVID-19 cases by comparing the vaccinated and unvaccinated groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The risk of being critically infected due to SAR-CoV-2 infection was 5.96 times higher (95% confidence interval, 5.63-6.38) among older individuals who were unvaccinated compared to those who received the bivalent COVID-19 vaccine.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings indicate that the bivalent vaccine reduces the disease burden of the SARS-CoV-2 omicron variant, particularly among the older population. Further studies are warranted to determine the effectiveness of booster doses of vaccines for SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Â© 2024 The Korean Academy of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Choi</LastName><ForeName>Young-Sook</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0002-0110-7315</Identifier><AffiliationInfo><Affiliation>Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ryu</LastName><ForeName>Sukhyun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8915-8167</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ryu Kyung</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0001-9577-9114</Identifier><AffiliationInfo><Affiliation>Korea Insurance Development Institute, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiara</LastName><ForeName>Achangwa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8231-9776</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Soojin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0008-9391-4691</Identifier><AffiliationInfo><Affiliation>Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Hojin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-5558-8890</Identifier><AffiliationInfo><Affiliation>Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Eunkyung</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1637-7067</Identifier><AffiliationInfo><Affiliation>Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0003-3613-3270</Identifier><AffiliationInfo><Affiliation>Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Young June</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0003-2733-0715</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Donghyok</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4756-6477</Identifier><AffiliationInfo><Affiliation>Director for Epidemiological Investigation Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea. vethyok@korea.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Won Suk</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0001-5874-4764</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea. cmcws@hanmail.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20220511F97-00</GrantID><Agency>Korea National Institute of Health, Korea Disease Prevention Agency</Agency><Country>Korea</Country></Grant><Grant><GrantID>RS-2023-KH140322</GrantID><Agency>Government-wide R&amp;D to Advance Infectious Disease Prevention and Control, Republic of Korea</Agency><Country>Korea</Country></Grant><Grant><GrantID>NRF-2020R1I1A3066471</GrantID><Acronym>NRF</Acronym><Agency>National Research Foundation of Korea</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Korean Med Sci</MedlineTA><NlmUniqueID>8703518</NlmUniqueID><ISSNLinking>1011-8934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Older People</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine Effectiveness</Keyword><Keyword MajorTopicYN="N">Vaccine, Bivalent</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>7</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355951</ArticleId><ArticleId IdType="pmc">PMC11444818</ArticleId><ArticleId IdType="doi">10.3346/jkms.2024.39.e258</ArticleId><ArticleId IdType="pii">39.e258</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293â1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Ali ST, Kim S, Jo J, Lim JS, Lee S, et al. Estimation of serial interval and reproduction number to quantify the transmissibility of SARS-CoV-2 omicron variant in South Korea. Viruses. 2022;14(3):533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8948735</ArticleId><ArticleId IdType="pubmed">35336939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu S, Han C, Kim D, Tsang TK, Cowling BJ, Lee S. Association between the relaxation of public health and social measures and transmission of the SARS-CoV-2 omicron variant in South Korea. JAMA Netw Open. 2022;5(8):e2225665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9375171</ArticleId><ArticleId IdType="pubmed">35960524</ArticleId></ArticleIdList></Reference><Reference><Citation>Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, et al. Bivalent omicron BA.1-adapted BNT162b2 booster in adults older than 55 years. N Engl J Med. 2023;388(3):214â227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933930</ArticleId><ArticleId IdType="pubmed">36652353</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng HF, Ackerson BK, Sy LS, Tubert JE, Luo Y, Qiu S, et al. mRNA-1273 bivalent (original and omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023;14(1):5851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10511551</ArticleId><ArticleId IdType="pubmed">37730701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CY, Chiew CJ, Pang D, Lee VJ, Ong B, Wang LF, et al. Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study. Lancet Infect Dis. 2023;23(12):1343â1348.</Citation><ArticleIdList><ArticleId IdType="pubmed">37543042</ArticleId></ArticleIdList></Reference><Reference><Citation>Central Quarantine Countermeasures Headquarters. COVID-19 response guideline in South Korea.  [Updated 2023].  [Accessed March 14, 2024].  
 https://www.ksid.or.kr/rang_board/list.html?num=5753&amp;code=notice3
.</Citation></Reference><Reference><Citation>Kim RK, Choe YJ, Jang EJ, Chae C, Hwang JH, Lee KH, et al. Comparative effectiveness of COVID-19 bivalent versus monovalent mRNA vaccines in the early stage of bivalent vaccination in Korea: October 2022 to January 2023. J Korean Med Sci. 2023;38(46):e396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10681846</ArticleId><ArticleId IdType="pubmed">38013649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi S, Choe YJ, Lim DS, Lee HR, Kim J, Kim YY, et al. Impact of national Covid-19 vaccination campaign, South Korea. Vaccine. 2022;40(26):3670â3675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9080122</ArticleId><ArticleId IdType="pubmed">35570077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu S, Ali ST, Noh E, Kim D, Lau EH, Cowling BJ. Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea. BMC Infect Dis. 2021;21(1):485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8154110</ArticleId><ArticleId IdType="pubmed">34039296</ArticleId></ArticleIdList></Reference><Reference><Citation>Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63(6):1055â1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536484</ArticleId><ArticleId IdType="pubmed">3879673</ArticleId></ArticleIdList></Reference><Reference><Citation>Why older adults can continue to benefit from covid-19 boosters. BMJ. 2023;382:1662.</Citation><ArticleIdList><ArticleId IdType="pubmed">37491033</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrone D, Mateo-Urdiales A, Sacco C, Riccardo F, Bella A, Ambrosio L, et al. Reduction of the risk of severe COVID-19 due to omicron compared to delta variant in Italy (November 2021 - February 2022) Int J Infect Dis. 2023;129:135â141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9877142</ArticleId><ArticleId IdType="pubmed">36708869</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi HW, Achangwa C, Park J, Lee SM, Lee NY, Jeon CH, et al. Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea. Front Immunol. 2023;14:1306604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10773891</ArticleId><ArticleId IdType="pubmed">38193075</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu S, Cowling BJ. Human Influenza Epidemiology. Cold Spring Harb Perspect Med. 2021;11(12):a038356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634793</ArticleId><ArticleId IdType="pubmed">32988982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>